The second Good Manufacturing Practice certification announced this morning for Tilray's Portuguese campus is key and enables the facility to progress towards exclusively supplying global medical markets with a significant cost advantage versus Tilray's Canadian operations, Stifel analyst Andrew Carter tells investors in a research note. He believes securing the certification "significantly enhances" Tilray's positioning for global medical opportunities. The analyst estimates Tilray's global medical revenues to grow 2.6 times over the next two years. While he's becoming "increasingly constructive" on Tilray due to its "continued strong execution," Carter keeps a Hold rating on the shares citing a "fulsome" valuation and "limited room for error around near-term cash needs."

In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on study dosing, a completed acquisition and a research partnership. ATAI ANNOUNCES DOSING... To see the rest of the story go to thefly.com. See Story Here

Tilray Brands celebrated 420 with an unprecedented display of community and craftsmanship, with over 20,000 guests attending Tilray's 420 weekend events of vibrant festivals and environmental advocacy. "As a company, we recognize the cultural significance of 420 and its impact on the cannabis industry. By celebrating this day across our brands, we not only honor the traditions of our consumers but also continue to push the boundaries of innovation and progress across both cannabis and craft beer industries," said Irwin Simon, Chairman and CEO, Tilray Brands. "Tilray Brands will continue to connect with consumers across the U.S. and international markets through more festivals, concerts, and events that bring together our passionate community. We will continue to collaborate with like-minded partners who share our values and vision and work towards creating meaningful experiences that are fun and that empower our consumers."